HomeCompareTLIS vs NOBL

TLIS vs NOBL: Dividend Comparison 2026

TLIS yields 70.42% · NOBL yields 2.17%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TLIS wins by $1.05M in total portfolio value
10 years
TLIS
TLIS
● Live price
70.42%
Share price
$2.84
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.07M
Annual income
$282,657.96
Full TLIS calculator →
NOBL
NOBL
● Live price
2.17%
Share price
$104.67
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.9K
Annual income
$249.78
Full NOBL calculator →

Portfolio growth — TLIS vs NOBL

📍 TLIS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTLISNOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TLIS + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TLIS pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TLIS
Annual income on $10K today (after 15% tax)
$5,985.92/yr
After 10yr DRIP, annual income (after tax)
$240,259.27/yr
NOBL
Annual income on $10K today (after 15% tax)
$184.52/yr
After 10yr DRIP, annual income (after tax)
$212.31/yr
At 15% tax rate, TLIS beats the other by $240,046.95/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TLIS + NOBL for your $10,000?

TLIS: 50%NOBL: 50%
100% NOBL50/50100% TLIS
Portfolio after 10yr
$547.6K
Annual income
$141,453.87/yr
Blended yield
25.83%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NOBL right now

TLIS
Analyst Ratings
1
Hold
3
Sell
Consensus: Sell
Altman Z
-12.3
Piotroski
1/9
NOBL
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TLIS buys
0
NOBL buys
0
No recent congressional trades found for TLIS or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTLISNOBL
Forward yield70.42%2.17%
Annual dividend / share$2.00$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$1.07M$22.9K
Annual income after 10y$282,657.96$249.78
Total dividends collected$914.3K$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: TLIS vs NOBL ($10,000, DRIP)

YearTLIS PortfolioTLIS Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$17,742$7,042.25$10,917$217.08+$6.8KTLIS
2$30,661$11,677.14$11,903$221.48+$18.8KTLIS
3$51,667$18,859.73$12,962$225.68+$38.7KTLIS
4$84,985$29,701.39$14,099$229.68+$70.9KTLIS
5$136,593$45,658.47$15,319$233.49+$121.3KTLIS
6$214,738$68,583.71$16,628$237.10+$198.1KTLIS
7$330,537$100,766.97$18,033$240.53+$312.5KTLIS
8$498,633$144,958.95$19,539$243.78+$479.1KTLIS
9$737,910$204,372.63$21,154$246.86+$716.8KTLIS
10$1,072,222$282,657.96$22,884$249.78+$1.05MTLIS

TLIS vs NOBL: Complete Analysis 2026

TLISStock

Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.

Full TLIS Calculator →

NOBLETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this TLIS vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TLIS vs SCHDTLIS vs JEPITLIS vs OTLIS vs KOTLIS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.